Business, energy, technology, markets and global industry news from Business News Today

desmoid tumors

PharmaDeviceNews desmoid tumors
Representative image: Clinician reviewing tumor imaging scans, highlighting the adult desmoid tumor treatment landscape as Immunome advances varegacestat through U.S. Food and Drug Administration review.
Pharma & Biotech

Immunome moves varegacestat into FDA review for adult desmoid tumors

Immunome has received U.S. Food and Drug Administration acceptance of its New Drug Application for varegacestat, an investigational once-daily oral gamma secretase inhibitor for adults with desmoid tumors. The application is supported by the Phase 3 RINGSIDE trial and carries an April 28, 2027 target action date, placing the targeted oncology company in a defined

Read More
Representative image of oncology drug discovery as Parabilis Medicines’ IPO surge puts Helicon peptides, zolucatetide, desmoid tumors, and Wnt-driven cancer treatment under sharper focus.
Pharma & Biotech

Parabilis Medicines IPO boom raises the bar for zolucatetide clinical execution

Find out how Parabilis Medicines’ IPO surge could reshape investor appetite for Helicon peptides and Wnt-driven oncology drugs.

Read More
Representative image of oncology researchers reviewing tumor imaging and clinical trial data, reflecting Immunome’s Phase 3 RINGSIDE results for varegacestat in adults with progressing desmoid tumors.
Pharma & Biotech

Why Immunome’s RINGSIDE data may reset expectations in desmoid tumor treatment

Discover how Immunome’s Phase 3 RINGSIDE data could reshape desmoid tumor treatment and gamma secretase inhibitor competition.

Read More
Pharma & Biotech

Immunome’s Phase 3 varegacestat data could redefine gamma secretase inhibition in desmoid tumors

Immunome is set to release pivotal Phase 3 varegacestat data in desmoid tumors. Find out what the RINGSIDE results could change for the field.

Read More